Showing results (2101-2110 of 2,317) with videos related to
Sort By:
Pageof 232
ACS Sensors|August 29, 2019
High Selectivity Gas Sensing and Charge Transfer of SnSe2Óscar Leonardo Camargo Moreira, Wei-Ying Cheng, Huei-Ru Fuh, et al.Lung Cancer (Amsterdam, Netherlands)|March 15, 2021
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)Ying Cheng, Tony S Mok, Xiangdong Zhou, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 6, 2022
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Gongyan Chen, Xiang Wang, et al.JCI Insight|August 8, 2022
SEMA7AR148W mutation promotes lipid accumulation and NAFLD progression via increased localization on the hepatocyte surfaceNan Zhao, Xiaoxun Zhang, Jingjing Ding, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 22, 2018
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian SubsetByoung Chul Cho, Busayamas Chewaskulyong, Ki Hyeong Lee, et al.Plos One|April 7, 2022
CHARM: COVID-19 Health Action Response for Marines-Association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 testMartha Sedegah, Chad Porter, Michael R Hollingdale, et al.Signal Transduction and Targeted Therapy|May 6, 2025
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trialYuankai Shi, Yi Ba, Junye Wang, et al.Chemical Research in Toxicology|August 15, 2015
Novel Nrf2/ARE activator, trans-Coniferylaldehyde, induces a HO-1-mediated defense mechanism through a dual p38α/MAPKAPK-2 and PK-N3 signaling pathwayHuang-Hui Chen, Tai-Chi Wang, Yen-Chen Lee, et al.Future Oncology (London, England)|October 3, 2024
Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050Xingxiang Pu, Juan Li, Bo Zhang, et al.Nucleic Acids Research|October 26, 2010
The European Nucleotide ArchiveRasko Leinonen, Ruth Akhtar, Ewan Birney, et al.Pageof 232